205 related articles for article (PubMed ID: 31076322)
1. Pharmacokinetics of isoniazid: The good, the bad, and the alternatives.
Erwin ER; Addison AP; John SF; Olaleye OA; Rosell RC
Tuberculosis (Edinb); 2019 May; 116S():S66-S70. PubMed ID: 31076322
[TBL] [Abstract][Full Text] [Related]
2. Pharmacogenetics of isoniazid-induced hepatotoxicity.
Perwitasari DA; Atthobari J; Wilffert B
Drug Metab Rev; 2015 May; 47(2):222-8. PubMed ID: 26095714
[TBL] [Abstract][Full Text] [Related]
3. Mechanism of isoniazid-induced hepatotoxicity: then and now.
Metushi I; Uetrecht J; Phillips E
Br J Clin Pharmacol; 2016 Jun; 81(6):1030-6. PubMed ID: 26773235
[TBL] [Abstract][Full Text] [Related]
4. CYP2E1 genotype and isoniazid-induced hepatotoxicity in patients treated for latent tuberculosis.
Vuilleumier N; Rossier MF; Chiappe A; Degoumois F; Dayer P; Mermillod B; Nicod L; Desmeules J; Hochstrasser D
Eur J Clin Pharmacol; 2006 Jun; 62(6):423-9. PubMed ID: 16770646
[TBL] [Abstract][Full Text] [Related]
5. Association of N-acetyltransferase 2 and cytochrome P450 2E1 gene polymorphisms with antituberculosis drug-induced hepatotoxicity in Western India.
Gupta VH; Amarapurkar DN; Singh M; Sasi P; Joshi JM; Baijal R; Ramegowda PH; Amarapurkar AD; Joshi K; Wangikar PP
J Gastroenterol Hepatol; 2013 Aug; 28(8):1368-74. PubMed ID: 23875638
[TBL] [Abstract][Full Text] [Related]
6. Role of CYP3A in isoniazid metabolism in vivo.
Liu K; Li F; Lu J; Gao Z; Klaassen CD; Ma X
Drug Metab Pharmacokinet; 2014; 29(2):219-22. PubMed ID: 24172716
[TBL] [Abstract][Full Text] [Related]
7. [Association between isoniazid induced hepatotoxicity and host N-acetyltransferase 2 polymorphisms].
Yang S; Guo JQ; Yan XF; Tang S
Zhonghua Jie He He Hu Xi Za Zhi; 2022 Feb; 45(2):227-232. PubMed ID: 35135095
[TBL] [Abstract][Full Text] [Related]
8. Hepatotoxicity during TB treatment in people with HIV/AIDS related to NAT2 polymorphisms in Pernambuco, Northeast Brazil.
Araujo-Mariz C; Militão de Albuquerque MFP; Lopes EP; Ximenes RAA; Lacerda HR; Miranda-Filho DB; Lustosa-Martins BB; Pastor AFP; Acioli-Santos B
Ann Hepatol; 2020; 19(2):153-160. PubMed ID: 31734174
[TBL] [Abstract][Full Text] [Related]
9. Efficacy, safety, and pharmacokinetics of isoniazid affected by NAT2 polymorphisms in patients with tuberculosis: A systematic review.
Surarak T; Chumnumwat S; Nosoongnoen W; Tragulpiankit P
Clin Transl Sci; 2024 Apr; 17(4):e13795. PubMed ID: 38629592
[TBL] [Abstract][Full Text] [Related]
10. Role of Inflammatory and Oxidative Stress, Cytochrome P450 2E1, and Bile Acid Disturbance in Rat Liver Injury Induced by Isoniazid and Lipopolysaccharide Cotreatment.
Hassan HM; Guo H; Yousef BA; Guerram M; Hamdi AM; Zhang L; Jiang Z
Antimicrob Agents Chemother; 2016 Sep; 60(9):5285-93. PubMed ID: 27324775
[TBL] [Abstract][Full Text] [Related]
11. Isoniazid hepatotoxicity associated with treatment of latent tuberculosis infection: a 7-year evaluation from a public health tuberculosis clinic.
Fountain FF; Tolley E; Chrisman CR; Self TH
Chest; 2005 Jul; 128(1):116-23. PubMed ID: 16002924
[TBL] [Abstract][Full Text] [Related]
12. Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatotoxicity in Tunisian patients with tuberculosis.
Ben Mahmoud L; Ghozzi H; Kamoun A; Hakim A; Hachicha H; Hammami S; Sahnoun Z; Zalila N; Makni H; Zeghal K
Pathol Biol (Paris); 2012 Oct; 60(5):324-30. PubMed ID: 21856096
[TBL] [Abstract][Full Text] [Related]
13. Pharmacogenetic association between
Khan S; Mandal RK; Elasbali AM; Dar SA; Jawed A; Wahid M; Mahto H; Lohani M; Mishra BN; Akhter N; Rabaan AA; Haque S
Biosci Rep; 2019 Jan; 39(1):. PubMed ID: 30509962
[TBL] [Abstract][Full Text] [Related]
14. Isoniazid-related hepatitis.
Vasudeva R; Woods B
Dig Dis; 1997; 15(6):357-67. PubMed ID: 9439900
[TBL] [Abstract][Full Text] [Related]
15. Risk factors of isoniazid-induced hepatotoxicity in Tunisian tuberculosis patients.
Ben Fredj N; Gam R; Kerkni E; Chaabane A; Chadly Z; Boughattas N; Aouam K
Pharmacogenomics J; 2017 Jul; 17(4):372-377. PubMed ID: 27089936
[TBL] [Abstract][Full Text] [Related]
16. N-acetyl transferase 2 and cytochrome P450 2E1 genes and isoniazid-induced hepatotoxicity in Brazilian patients.
Santos NP; Callegari-Jacques SM; Ribeiro Dos Santos AK; Silva CA; Vallinoto AC; Fernandes DC; de Carvalho DC; Santos SE; Hutz MH
Int J Tuberc Lung Dis; 2013 Apr; 17(4):499-504. PubMed ID: 23394127
[TBL] [Abstract][Full Text] [Related]
17. Genetic polymorphisms of NAT2, CYP2E1 and GST enzymes and the occurrence of antituberculosis drug-induced hepatitis in Brazilian TB patients.
Teixeira RL; Morato RG; Cabello PH; Muniz LM; Moreira Ada S; Kritski AL; Mello FC; Suffys PN; Miranda AB; Santos AR
Mem Inst Oswaldo Cruz; 2011 Sep; 106(6):716-24. PubMed ID: 22012226
[TBL] [Abstract][Full Text] [Related]
18. Association of NAT2, GST and CYP2E1 polymorphisms and anti-tuberculosis drug-induced hepatotoxicity.
Singla N; Gupta D; Birbian N; Singh J
Tuberculosis (Edinb); 2014 May; 94(3):293-8. PubMed ID: 24637014
[TBL] [Abstract][Full Text] [Related]
19. A proposal for an individualized pharmacogenetic-guided isoniazid dosage regimen for patients with tuberculosis.
Jung JA; Kim TE; Lee H; Jeong BH; Park HY; Jeon K; Kwon OJ; Ko JW; Choi R; Woo HI; Koh WJ; Lee SY
Drug Des Devel Ther; 2015; 9():5433-8. PubMed ID: 26491254
[TBL] [Abstract][Full Text] [Related]
20. Selected pharmaceutical excipient prevent isoniazid and rifampicin induced hepatotoxicity.
Shih TY; Ho SC; Hsiong CH; Huang TY; Hu OY
Curr Drug Metab; 2013 Jul; 14(6):720-8. PubMed ID: 23701163
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
